Maria Hafez, MD, discusses factors such as HER2 status, lymph node negativity, and risk stratification that influence the selection of adjuvant treatment approaches for patients with early-stage HER2-positive breast cancer and expands on pivotal data that have changed the paradigm.
Experts reflect on the evolving landscape of biomarker testing in lung cancer, examining its crucial role in treatment decisions and advancements in perioperative and adjuvant therapies.
Shared insight from key opinion leaders on the value of molecular testing in patients with resectable non–small cell lung cancer and how it can be applied.
Switching their focus to the adjuvant setting of resectable NSCLC, expert panelists identify treatment options in this setting and review the clinical data behind them.